Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TYMP | P19971 | 2/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | UBE2N | P61088 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5437075 | 0.86 | KDM4E (0.41) | KDM4EALDH1A1HPGDMAPTKDM5B | |
| SCHEMBL5443537 | 0.85 | ALDH1A1 (0.44) | KDM4EALDH1A1HPGDMAPTKMT2A | |
| SCHEMBL5446598 | 0.84 | BRDT (0.41) | KDM4EALDH1A1HSD17B10KMT2A | |
| SCHEMBL5446767 | 0.84 | KMT2A (0.45) | KDM4EALDH1A1HPGDMAPTPKM | |
| SCHEMBL5442836 | 0.84 | TP53 (0.44) | KDM4EALDH1A1HPGDMAPTKDM4C | |
| SCHEMBL5448031 | 0.82 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTKMT2A | |
| SCHEMBL6050843 | 0.77 | PDE4A (0.42) | KDM4EALDH1A1HPGDMAPTHSD17B10 | |
| SCHEMBL5443099 | 0.75 | PGR (0.45) | ALDH1A1MAPTKDM5BHSD17B10KMT2A | |
| SCHEMBL5438415 | 0.74 | XDH (0.45) | HPGDMAPTKDM5BTYMPKMT2A | |
| SCHEMBL9412461 | 0.74 | KDM4E (0.59) | KDM4EALDH1A1HPGDMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043000-A1 | Immunosuppresive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2007-02-22 | — | — | US | disclosed |
| EP-1636232-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA Bioscience nv (BE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004104005-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2004-12-02 | — | — | WO | disclosed |
| EP-1479682-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA Bioscience nv (BE) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043000-A1 | Immunosuppresive effects of pteridine derivatives | TPMT, FKBP5, RRP15 | KDM4E 1686/4885ALDH1A1 1767/4885HPGD 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.